Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 20/20 | 1.00 |
| ▸ | MST1R | Q04912 | 4/20 | 0.69 |
| ▸ | HGF | P14210 | 2/20 | 0.69 |
| ▸ | KDR | P35968 | 2/20 | 0.63 |
| ▸ | AURKA | O14965 | 1/20 | 0.57 |
| ▸ | EGFR | P00533 | 1/20 | 0.57 |
| ▸ | LCK | P06239 | 1/20 | 0.57 |
| ▸ | CSF1R | P07333 | 1/20 | 0.57 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.57 |
| ▸ | FLT4 | P35916 | 1/20 | 0.57 |
| ▸ | TEK | Q02763 | 1/20 | 0.57 |
| ▸ | BTK | Q06187 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2866137 | 1.00 | MET (1.00) | METMST1RHGFKDRAURKA | |
| SCHEMBL2857730 | 1.00 | MET (1.00) | METMST1RHGFKDRAURKA | |
| SCHEMBL2858159 | 0.91 | MET (0.84) | METMST1RHGFKDRAURKA | |
| SCHEMBL13511859 | 0.91 | MET (0.84) | METMST1RHGFKDRAURKA | |
| SCHEMBL15405310 | 0.87 | MET (0.78) | METMST1RHGFKDRAURKA | |
| SCHEMBL2866160 | 0.85 | MET (0.76) | METMST1RHGFKDRAURKA | |
| SCHEMBL2854277 | 0.85 | MET (0.78) | METMST1RHGFKDRAURKA | |
| SCHEMBL13511934 | 0.84 | MET (1.00) | METMST1RHGFKDRAURKA | |
| SCHEMBL13511937 | 0.84 | MET (1.00) | METMST1RHGFKDRAURKA | |
| SCHEMBL13511900 | 0.84 | MET (0.78) | METMST1RHGFKDRAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1827434-B1 | QUINOLINES AND QUINAZOLINE ANALOGS AND THEIR USE AS MEDICAMENTS FOR TREATING CANCER | AMGEN INC (US) | 2014-01-15 | — | — | EP | disclosed |
| US-7652009-B2 | Substituted heterocycles and methods of use | AMGEM INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-7652009-B2 | Substituted heterocycles and methods of use | AMGEM INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-7652009-B2 | Substituted heterocycles and methods of use | AMGEM INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-20060252777-A1 | Substituted heterocycles and methods of use | AMGEN INC. (US) | 2006-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252777-A1 | Substituted heterocycles and methods of use | HGF, HGFAC, MET | MET 3/4885MST1R 815/4885HGF 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.